Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District

Objective: analyzing the acquisition and monthly costs for patients on modern fixed-dose antihypertensive combinations in three regions of the Far Eastern Federal District.Material and methods. Intra-group analysis of retail of antihypertensive drugs for 2019 in drugstores of the Khabarovsk Region,...

Full description

Bibliographic Details
Published in:FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology
Main Authors: M. S. Soboleva, E. E. Loskutova, М. С. Соболева, Е. Е. Лоскутова
Format: Article in Journal/Newspaper
Language:Russian
Published: IRBIS LLC 2021
Subjects:
регионы Дальневосточного федерального округа
cost of therapy
fixed-dose combinations
regions of the Far Eastern Federal District
стоимость терапии
фиксированные комбинации
Sakhalin
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/485
https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.061
id ftjpharmaeconom:oai:oai.farmaec.elpub.ru:article/485
record_format openpolar
institution Open Polar
collection PharmacoEconomics - Modern pharmacoeconomics and pharmacoepidemiology
op_collection_id ftjpharmaeconom
language Russian
topic регионы Дальневосточного федерального округа
cost of therapy
fixed-dose combinations
regions of the Far Eastern Federal District
стоимость терапии
фиксированные комбинации
spellingShingle регионы Дальневосточного федерального округа
cost of therapy
fixed-dose combinations
regions of the Far Eastern Federal District
стоимость терапии
фиксированные комбинации
M. S. Soboleva
E. E. Loskutova
М. С. Соболева
Е. Е. Лоскутова
Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District
topic_facet регионы Дальневосточного федерального округа
cost of therapy
fixed-dose combinations
regions of the Far Eastern Federal District
стоимость терапии
фиксированные комбинации
description Objective: analyzing the acquisition and monthly costs for patients on modern fixed-dose antihypertensive combinations in three regions of the Far Eastern Federal District.Material and methods. Intra-group analysis of retail of antihypertensive drugs for 2019 in drugstores of the Khabarovsk Region, Sakhalin Region, Amur Region (n=100) was carried out. The calculation of the monthly cost of therapy was performed and total sales indicators were identified. Statistical analysis: dispersion analysis, Spearman's rank correlation coefficient, Kruskal–Wallis test.Results. The maximum demand in patients among combinations of -blockers in the price range of 100-500 rubles: atenolol+chlortalidone; bisoprolol+amlodipine. In the grope of combinations of angiotensin-converting enzyme inhibitors with diuretics/calcium channel blockers, the most often acquired were: perindopril/ramipril+indapamide/amlodipine, enalapril+hydrochlorothiazide – in the price segment of 500–1000 rubles. Preferences for the use of combinations of angiotensin II receptor blockers+diuretic/calcium channel blockers: valsartan+amlodipine with a monthly cost of therapy of 300–500 rubles; losartan+hydrochlorothiazide – 100–500 rubles and azilsartan+chlortalidonee – 500–1000 rubles. The most popular three-component drugs were valsartan+amlodipine+hydrochlorothiazide, perindopril+amlodipine+indapamide with a monthly cost over 500 rubles. Differences in the acquisition structure of fixed-dose antihypertensive combinations between regions were statistically significant.Conclusion. The share of sales of combined antihypertensive drugs remains insignificant. The main selection criteria within an international nonproprietary name are affordability or trust in a brand. The presence of a reliable correlation of the acquisition structure with the region proves the influence of regional preferences of specialists in drug prescribing. Цель: анализ приобретения и месячных затрат пациентов на современные фиксированные антигипертензивные комбинации в трех регионах ...
format Article in Journal/Newspaper
author M. S. Soboleva
E. E. Loskutova
М. С. Соболева
Е. Е. Лоскутова
author_facet M. S. Soboleva
E. E. Loskutova
М. С. Соболева
Е. Е. Лоскутова
author_sort M. S. Soboleva
title Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District
title_short Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District
title_full Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District
title_fullStr Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District
title_full_unstemmed Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District
title_sort analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the far eastern federal district
publisher IRBIS LLC
publishDate 2021
url https://www.pharmacoeconomics.ru/jour/article/view/485
https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.061
genre Sakhalin
genre_facet Sakhalin
op_source FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 14, No 1 (2021); 41-49
ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 14, No 1 (2021); 41-49
2070-4933
2070-4909
op_relation https://www.pharmacoeconomics.ru/jour/article/view/485/360
Hazra N.C., Rudisill C., Jackson S.H., Gulliford M.C. Cost-effectiveness of antihypertensive therapy in patients older than 80 years: cohort study and Markov model. Value Health. 2019; 22 (12): 1362–9. https://doi.org/10.1016/j.jval.2019.08.001.
Gu D., He J., Coxson P.G., et al. The costeffectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study. PLoS Med. 2015; 12 (8): e1001860. https://doi.org/10.1371/journal.pmed.1001860.
González-Gómez S., Meléndez-Gomez M.A., López-Jaramillo P. Fixed-dose combination therapy to improve hypertension treatment and control in Latin America. Arch Cardiol Mex. 2018; 88 (2): 129−35. https://doi.org/10.1016/j.acmx.2017.06.001.
Moran A.E., Odden M.C., Thanataveerat A., et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015; 372 (5): 447–55. https://doi.org/10.1056/NEJMsa1406751.
Salam A., Huffman M.D., Kanukula R., et al. Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: an overview of efficacy, safety, and cost. J Clin Hypertens (Greenwich). 2020; 22 (10): 1769–79. https://doi.org/10.1111/jch.14009.
Düsing R., Waeber B., Destro M., et al. Triplecombination therapy in the treatment of hypertension: a review of the evidence. J Hum Hypertens. 2017; 31 (8): 501−10. https://doi.org/10.1038/jhh.2017.5.
Laurent S., Bejan-Angoulvant T., Boutouyrie P. Prescription of fixed dose combinations of antihypertensive drugs. Rev Prat. 2019; 69 (10): 1094−8.
Mazón P., Galve E., Gómez J., et al. Medical expert consensus in AH on the clinical use of triple fixed-dose antihypertensive therapy in Spain. Hipertens Riesgo Vasc. 2016; 33 (4): 133–44. https://doi.org/10.1016/j.hipert.2016.03.001.
Ishida T., Oh A., Hiroi Sh., et al. Treatment patterns and adherence to antihypertensive combination therapies in Japan using a claims database. Hypertens Res. 2019; 42 (2): 249−56. https://doi.org/10.1038/s41440-018-0127-0.
Bramlage P., Schmidt S., Sims H. Fixed-dose vs free-dose combinations for the management of hypertension – аn analysis of 81 958 patients. J Clin Hypertens (Greenwich). 2018; 20 (4): 705−15. https://doi.org/10.1111/jch.13240.
Deshmukh K.B., Qian J., Garza K.B., et al. Health сare сosts associated with addition, titration, and switching antihypertensive medications after first-line treatment: results from a commercially insured sample. J Manag Care Spec Pharm. 2017; 23 (6): 691−9. https://doi.org/10.18553/jmcp.2017.23.6.691.
Wang X., Chen H., Ej E., et al. Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Rev Pharmacoecon Outcomes Res. 2020: 1–8. https://doi.org/10.1080/14737167.2020.1800457.
Xie X., He T., Kang J., et al. Cost-effectiveness analysis of intensive hypertension control in China. Prev Med. 2018; 111: 110−4. https://doi.org/10.1016/j.ypmed.2018.02.033.
Ziyad A., Yasser A., Adnan A., et al. Соst-effectiveness of more intensive blood pressure treatment in patients with high risk of cardiovascular disease in Saudi Arabia: a modelling study of metaanalysis. Int J Hypertens. 2019; 2019: 6019401. https://doi.org/10.1155/2019/6019401.
Клинические рекомендации. Артериальная гипертензия у взрослых. 2020. Российское кардиологическое общество. URL: https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf (дата обращения 26.03.2021).
Здравоохранение в России 2019. Приложение к сборнику (информация в разрезе субъектов Российской Федерации). URL: https://rosstat.gov.ru/folder/210/document/13218 (дата обращения 26.03.21).
Справочник организаций России. Медицина. Аптеки. URL: https://www.orgpage.ru/rossiya/аптеки/ (дата обращения 26.03.2021).
Калькулятор расчета ошибки и размера выборки. FDF group. URL: https://fdfgroup.ru/poleznayainformatsiya/stati/vyborka-tipyvyborok-raschet-oshibki-vyborki/#1_anchor (дата обращения 26.03.2021).
Кошевой О.С., Карпова М.К. Определение объема выборочной совокупности при проведении региональных социологических исследований. Известия высших учебных заведений. Поволжский регион. Общественные науки. 2011; 2 (18): 98−104.
ATC/DDD Index. URL: https://www.whocc.no/atc_ddd_index/?code=C (дата обращения 26.03.2021).
https://www.pharmacoeconomics.ru/jour/article/view/485
doi:10.17749/2070-4909/farmakoekonomika.2021.061
op_rights Authors who publish with this journal agree to the following terms:Authors grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Авторы, публикующиеся в данном журнале, соглашаются со следующим:Авторы предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access).
op_doi https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.06110.1016/j.jval.2019.08.00110.1371/journal.pmed.100186010.1016/j.acmx.2017.06.00110.1056/NEJMsa140675110.1111/jch.1400910.1038/jhh.2017.510.1016/j.hipert.2016.03.00110.1038/s41440-018-0127-010.111
container_title FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology
container_volume 14
container_issue 1
container_start_page 41
op_container_end_page 49
_version_ 1809938217736077312
spelling ftjpharmaeconom:oai:oai.farmaec.elpub.ru:article/485 2024-09-09T20:05:48+00:00 Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District Анализ приобретения и месячной стоимости антигипертензивной терапии современными фиксированными комбинациями в регионах Дальневосточного федерального округа M. S. Soboleva E. E. Loskutova М. С. Соболева Е. Е. Лоскутова 2021-04-27 application/pdf https://www.pharmacoeconomics.ru/jour/article/view/485 https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.061 rus rus IRBIS LLC https://www.pharmacoeconomics.ru/jour/article/view/485/360 Hazra N.C., Rudisill C., Jackson S.H., Gulliford M.C. Cost-effectiveness of antihypertensive therapy in patients older than 80 years: cohort study and Markov model. Value Health. 2019; 22 (12): 1362–9. https://doi.org/10.1016/j.jval.2019.08.001. Gu D., He J., Coxson P.G., et al. The costeffectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study. PLoS Med. 2015; 12 (8): e1001860. https://doi.org/10.1371/journal.pmed.1001860. González-Gómez S., Meléndez-Gomez M.A., López-Jaramillo P. Fixed-dose combination therapy to improve hypertension treatment and control in Latin America. Arch Cardiol Mex. 2018; 88 (2): 129−35. https://doi.org/10.1016/j.acmx.2017.06.001. Moran A.E., Odden M.C., Thanataveerat A., et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015; 372 (5): 447–55. https://doi.org/10.1056/NEJMsa1406751. Salam A., Huffman M.D., Kanukula R., et al. Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: an overview of efficacy, safety, and cost. J Clin Hypertens (Greenwich). 2020; 22 (10): 1769–79. https://doi.org/10.1111/jch.14009. Düsing R., Waeber B., Destro M., et al. Triplecombination therapy in the treatment of hypertension: a review of the evidence. J Hum Hypertens. 2017; 31 (8): 501−10. https://doi.org/10.1038/jhh.2017.5. Laurent S., Bejan-Angoulvant T., Boutouyrie P. Prescription of fixed dose combinations of antihypertensive drugs. Rev Prat. 2019; 69 (10): 1094−8. Mazón P., Galve E., Gómez J., et al. Medical expert consensus in AH on the clinical use of triple fixed-dose antihypertensive therapy in Spain. Hipertens Riesgo Vasc. 2016; 33 (4): 133–44. https://doi.org/10.1016/j.hipert.2016.03.001. Ishida T., Oh A., Hiroi Sh., et al. Treatment patterns and adherence to antihypertensive combination therapies in Japan using a claims database. Hypertens Res. 2019; 42 (2): 249−56. https://doi.org/10.1038/s41440-018-0127-0. Bramlage P., Schmidt S., Sims H. Fixed-dose vs free-dose combinations for the management of hypertension – аn analysis of 81 958 patients. J Clin Hypertens (Greenwich). 2018; 20 (4): 705−15. https://doi.org/10.1111/jch.13240. Deshmukh K.B., Qian J., Garza K.B., et al. Health сare сosts associated with addition, titration, and switching antihypertensive medications after first-line treatment: results from a commercially insured sample. J Manag Care Spec Pharm. 2017; 23 (6): 691−9. https://doi.org/10.18553/jmcp.2017.23.6.691. Wang X., Chen H., Ej E., et al. Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Rev Pharmacoecon Outcomes Res. 2020: 1–8. https://doi.org/10.1080/14737167.2020.1800457. Xie X., He T., Kang J., et al. Cost-effectiveness analysis of intensive hypertension control in China. Prev Med. 2018; 111: 110−4. https://doi.org/10.1016/j.ypmed.2018.02.033. Ziyad A., Yasser A., Adnan A., et al. Соst-effectiveness of more intensive blood pressure treatment in patients with high risk of cardiovascular disease in Saudi Arabia: a modelling study of metaanalysis. Int J Hypertens. 2019; 2019: 6019401. https://doi.org/10.1155/2019/6019401. Клинические рекомендации. Артериальная гипертензия у взрослых. 2020. Российское кардиологическое общество. URL: https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf (дата обращения 26.03.2021). Здравоохранение в России 2019. Приложение к сборнику (информация в разрезе субъектов Российской Федерации). URL: https://rosstat.gov.ru/folder/210/document/13218 (дата обращения 26.03.21). Справочник организаций России. Медицина. Аптеки. URL: https://www.orgpage.ru/rossiya/аптеки/ (дата обращения 26.03.2021). Калькулятор расчета ошибки и размера выборки. FDF group. URL: https://fdfgroup.ru/poleznayainformatsiya/stati/vyborka-tipyvyborok-raschet-oshibki-vyborki/#1_anchor (дата обращения 26.03.2021). Кошевой О.С., Карпова М.К. Определение объема выборочной совокупности при проведении региональных социологических исследований. Известия высших учебных заведений. Поволжский регион. Общественные науки. 2011; 2 (18): 98−104. ATC/DDD Index. URL: https://www.whocc.no/atc_ddd_index/?code=C (дата обращения 26.03.2021). https://www.pharmacoeconomics.ru/jour/article/view/485 doi:10.17749/2070-4909/farmakoekonomika.2021.061 Authors who publish with this journal agree to the following terms:Authors grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). Авторы, публикующиеся в данном журнале, соглашаются со следующим:Авторы предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access). FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 14, No 1 (2021); 41-49 ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 14, No 1 (2021); 41-49 2070-4933 2070-4909 регионы Дальневосточного федерального округа cost of therapy fixed-dose combinations regions of the Far Eastern Federal District стоимость терапии фиксированные комбинации info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 2021 ftjpharmaeconom https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.06110.1016/j.jval.2019.08.00110.1371/journal.pmed.100186010.1016/j.acmx.2017.06.00110.1056/NEJMsa140675110.1111/jch.1400910.1038/jhh.2017.510.1016/j.hipert.2016.03.00110.1038/s41440-018-0127-010.111 2024-07-01T03:01:05Z Objective: analyzing the acquisition and monthly costs for patients on modern fixed-dose antihypertensive combinations in three regions of the Far Eastern Federal District.Material and methods. Intra-group analysis of retail of antihypertensive drugs for 2019 in drugstores of the Khabarovsk Region, Sakhalin Region, Amur Region (n=100) was carried out. The calculation of the monthly cost of therapy was performed and total sales indicators were identified. Statistical analysis: dispersion analysis, Spearman's rank correlation coefficient, Kruskal–Wallis test.Results. The maximum demand in patients among combinations of -blockers in the price range of 100-500 rubles: atenolol+chlortalidone; bisoprolol+amlodipine. In the grope of combinations of angiotensin-converting enzyme inhibitors with diuretics/calcium channel blockers, the most often acquired were: perindopril/ramipril+indapamide/amlodipine, enalapril+hydrochlorothiazide – in the price segment of 500–1000 rubles. Preferences for the use of combinations of angiotensin II receptor blockers+diuretic/calcium channel blockers: valsartan+amlodipine with a monthly cost of therapy of 300–500 rubles; losartan+hydrochlorothiazide – 100–500 rubles and azilsartan+chlortalidonee – 500–1000 rubles. The most popular three-component drugs were valsartan+amlodipine+hydrochlorothiazide, perindopril+amlodipine+indapamide with a monthly cost over 500 rubles. Differences in the acquisition structure of fixed-dose antihypertensive combinations between regions were statistically significant.Conclusion. The share of sales of combined antihypertensive drugs remains insignificant. The main selection criteria within an international nonproprietary name are affordability or trust in a brand. The presence of a reliable correlation of the acquisition structure with the region proves the influence of regional preferences of specialists in drug prescribing. Цель: анализ приобретения и месячных затрат пациентов на современные фиксированные антигипертензивные комбинации в трех регионах ... Article in Journal/Newspaper Sakhalin PharmacoEconomics - Modern pharmacoeconomics and pharmacoepidemiology FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology 14 1 41 49

Similar Items